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Background: The purpose of this study was to identify preoperative patient characteristics associated with the
incidence of positive surgical margins or lymph node extracapsular extension (ECE), which necessitate adjuvant
chemoradiation after transoral robotic surgery (TORS).
Methods: We conducted a single institution retrospective study of 34 consecutive patients with primary
oropharyngeal cancer who underwent TORS. All imaging was reviewed by a single neuroradiologist. Surgical
margins and ECE status were determined by a single head and neck pathologist. Associations of preoperative
patient characteristics with positive surgical margins and lymph node ECE were examined using univariate analysis.
Independent predictors of these outcomes were determined using logistic regression.
Results: Preoperatively, the majority of patients had early-stage disease (7 cT1 and 21 cT2; 10 cN0). Positive margins
occurred in 4 (12 %) patients. A clinically positive lymph node was seen in 23 (68 %) patients. Neck dissection was
performed in 29 (85 %) patients, among whom 19 had a pathologically positive lymph node and 15 had nodal ECE.
Logistic regression showed that larger preoperative lymph node size was an independent predictor of ECE (odds
ratio, 13.32 [95 % CI, 1.46–121.43]). Among the 21 patients with a clinically positive lymph node who underwent
neck dissection, ECE was present more often in patients with a preoperative node size ≥ 3.0 vs. < 3.0 cm (92 % vs.
44 %, P = 0.046). There was no patient characteristic associated with positive margins.
Conclusions: Patients with a larger preoperative lymph node appear more likely to have ECE, and thus be treated
with chemoradiation after TORS, with a potentially higher rate of toxicity. Lymph node size should be taken into
account when deciding upon treatment approaches. Further research is needed to validate these results.
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Minimally invasive transoral robotic surgery (TORS) has
been rapidly adopted across the country for the treat-
ment of oropharyngeal squamous cell carcinoma
(OPSCC) [1]. The outcomes following TORS have been
encouraging, with less morbidity than conventional sur-
gery [2, 3]. However, the use of adjuvant therapy after
TORS remains high [4]. Based on the landmark studies
by the RTOG and EORTC, the addition of cisplatin
chemotherapy is indicated in patients with extracapsular
extension (ECE) of metastatic lymph nodes or positive
surgical margins [5–7]. Although recent analysis has
called into question the validity of these guidelines [8],
adjuvant chemoradiation remains the standard of care
for these high-risk patients, pending further clinical
trials. Additionally, positive margins and nodal ECE are
indications for dose escalation of radiation therapy [9].
Recent evidence shows nearly 75 % of newly diagnosed
OPSCC in the United States are human papillomavirus
(HPV) associated, with a more favorable prognosis, and
as a result current trials investigate the de-escalation of
therapy [10–12]. The potential toxicity advantages of
TORS, however, may be negated when patients subse-
quently receive adjuvant high dose radiation with con-
current chemotherapy. Recent data suggest that
trimodality therapy including TORS may result in in-
creased toxicity compared to treatment with definitive
chemoradiation [13]. The addition of chemotherapy, es-
calation of adjuvant radiation dose, and depth of resec-
tion have also been associated with an increased
incidence of soft tissue necrosis after TORS [14].
Thus it remains important to carefully select patients
for TORS. The purpose of this study is to obtain pre-
treatment predictors for margin positivity and ECE, to
help optimize patient selection for TORS.
Methods
Patients and data collection
The medical records of all OPSCC patients treated at
Yale-New Haven Hospital between January 1, 2010, and
November 30, 2014, were retrospectively reviewed.
Patients undergoing TORS for a primary OPSCC were
extracted. Patients treated for recurrent disease were ex-
cluded. This study did not include other surgical modal-
ities such as open surgery, because the incidence of
positive margins may vary depending on surgical ap-
proach. All cases were discussed at a multi-disciplinary
tumor board attended by neuroradiology, pathology, ra-
diation oncology, medical oncology, and otolaryngology.
Patients were selected for TORS if there was a consen-
sus at tumor board that there was a high likelihood of
achieving negative margins and if the lymph nodes did
not demonstrate obvious radiographic evidence of ECE
on preoperative examination and imaging.Information including tumor location, smoking status,
p16 status, preoperative tumor size, preoperative lymph
node size, neck dissection, surgical margins, ECE, patho-
logic tumor size, pathologic lymph node size, and receipt
of adjuvant therapy were obtained. Preoperative sizes
were measured from patient imaging. In order to ensure
consistency, all imaging scans were re-reviewed by a sin-
gle board-certified neuroradiologist, who was blinded to
the results of pathologic ECE and margin status. The
neuroradiologist identified radiographic ECE based on
the presence of irregular borders of the lymph node cap-
sule as well as perinodal fat infiltration. Tumor size was
recorded as the largest diameter measured, and lymph
node size was recorded as the long-axis diameter of the
largest metastatic lymph node in each patient. Surgical
margins and the presence of ECE were all re-reviewed
for the purposes of this study by a single board-certified
head and neck pathologist. In addition, the distance
from tumor to the margin was obtained, as well as the
extent of ECE, and the ECE grade based on criteria
established by Lewis et al. [15]. Surgical margins after
TORS were considered positive when tumor cells were
present at the resection border.
Statistical analysis
We analyzed multiple preoperative characteristics of these
patients as independent variables to identify possible asso-
ciations to nodal ECE or positive surgical margins. All
analyses were performed using SPSS version 19 (IBM
SPSS, Armonk, NY). Chi-square and logistic regression
analysis were used to identify predictors of positive mar-
gins and ECE. Factors associated with a P value < 0.10 in
univariate analyses were included in multivariable analysis.
The study was approved by the Yale University Institu-
tional Review Board, and informed consent was waived.
Results
Patient characteristics
A total of 34 patients with primary squamous cell carcin-
oma of the oropharynx undergoing TORS were identified.
Overall patient characteristics are summarized in Table 1.
The median age was 56.5 years, 28 (82 %) patients had
p16-positive tumors, and 21 (62 %) patients were current
or former smokers. Preoperatively, the majority of patients
had early-stage disease, with seven (21 %) T1 tumors and
21 (62 %) T2 tumors. A total of 10 (29 %) patients were
staged cN0. The overall clinical staging of our patients
was distributed as: two (6 %) stage I, six (18 %) stage II, 11
(33 %) stage III, and 14 (42 %) stage IVA. The overall
pathologic staging of our patients was distributed as: four
(12 %) stage I, five (15 %) stage II, six (18 %) stage III, and
18 (53 %) stage IVA. In total, eight (24 %) patients were
upstaged while three (9 %) patients were downstaged post-
operatively. The other 21 (62 %) patients remained the




Male 25 (74 %)
Female 9 (27 %)
Location
Tonsil 17 (50 %)
Base of Tongue 16 (47 %)
Soft Palate 1 (3 %)
Smoking
Smoker 21 (62 %)
Non-Smoker 13 (38 %)
p16
Positive 28 (82 %)
Negative 3 (9 %)
Undetermined 3 (9 %)
Preoperative Tumor Size (median, n = 25) 2.20 cm
Postoperative Tumor Size (median, n = 31) 2.20 cm
Preoperative Node Size (median, n = 23) 3.00 cm
Postoperative Node Size (median, n = 19) 3.50 cm
Preoperative T Stage
T0 3 (9 %)
T1 7 (21 %)
T2 21 (62 %)
T3 2 (6 %)
T4 0 (0 %)
Unknown 1 (3 %)
Postoperative T Stage
T1 12 (35 %)
T2 17 (50 %)
T3 4 (12 %)
T4 0 (0 %)
Unknown 1 (3 %)
Preoperative N Stage
N0 10 (29 %)
N1 9 (27 %)
N2 14 (41 %)
N3 0 (0 %)
Unknown 1 (3 %)
Postoperative N Stage
N0 13 (38 %)
N1 3 (9 %)
N2 17 (50 %)
N3 1 (3 %)
Table 1 Patient characteristics (n = 34) (Continued)
Preoperative Overall Stage
Stage I 2 (6 %)
Stage II 6 (18 %)
Stage III 11 (33 %)
Stage IVA 14 (42 %)
Unknown 1 (3 %)
Postoperative Overall Stage
Stage I 4 (12 %)
Stage II 5 (15 %)
Stage III 6 (18 %)
Stage IVA 18 (53 %)
Unknown 1 (3 %)
Lymph Nodes
Positive node on imaging 23 (68 %)
Neck dissection performed 29 (85 %)
Positive node on dissection 19 (56 %)
ECE present 15 (44 %)
No ECE present 14 (41 %)
Extent of ECE (median, n = 13) 2.00 mm
ECE Lewis Grade
0 1 (3 %)
1 4 (12 %)
2 7 (21 %)
3 7 (21 %)
4 1 (3 %)
Surgical Margins
Positive 4 (12 %)
Negative 30 (88 %)
Distance to negative margins (median) 3.00 mm
Adjuvant Therapy
None 10 (29 %)
Radiation therapy alone 7 (21 %)
Chemoradiation therapy 17 (50 %)
ECE indicates extracapsular extension
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ing staging information. The median time between pre-
treatment imaging studies and surgery was 29 days. Based
on measurements from imaging, the median preoperative
tumor size was 2.20 cm, and the median preoperative
lymph node size was 3.00 cm.
A positive lymph node was detected on preoperative
imaging in 23 (68 %) patients. The decision to classify a
node as positive was based on review of imaging by a
single head and neck radiologist. Neck dissection was
performed in 29 (85 %) total patients, including 21
(62 %) who had at least one node detected on imaging.
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positive for carcinoma after surgery, and 15 (44 %) had
nodal ECE. Only one patient without clinically detected
nodes was found to be node positive after surgery, and
this patient did not have ECE. Of the 19 (56 %) patients
with at least one positive node after surgery, the median
pathologic size was 3.50 cm.
Adjuvant therapy was given to 24 (71 %) patients, with
seven (21 %) receiving radiation therapy alone and 17
(50 %) receiving chemoradiation. This was due to posi-
tive margins in one (3 %) patient, ECE in 13 (38 %)
patients, and both indications in one (3 %) patient. Two
(6 %) patients who had positive nodes detected prior to
surgery but did not undergo neck dissection also re-
ceived adjuvant chemoradiation. Three (9 %) patients
were confirmed as deceased at times of 12, 23, and
36 months after surgery, among whom one (3 %) re-
ceived no adjuvant therapy, one (3 %) received adjuvant
chemoradiation, and one (3 %) received adjuvant radi-
ation, respectively. Further survival analysis was not per-
formed due to the small number of mortality events.
Association between patient characteristics and positive
margins
No patient characteristic was associated with positive
margins (Table 2). Evaluated characteristics include
smoking history, p16 status, tumor size, and the time
interval from pretreatment imaging to surgery. Twenty-
five patients (74 %) were evaluable for the examination
of the association between preoperative tumor size and
margin positivity. Nine patients were excluded due to a
lack of preoperative tumor size due to the primary
tumor not being visible on imaging (two patients), a lack
of discrete tumor borders on imaging (three patients), or
the absence of preoperative imaging prior to excisional
biopsy (two patients) or tonsillectomy for presumed ton-
sillitis (two patients). Positive margins occurred in four
patients (12 %). Logistic regression analysis did not show
a significant association between preoperative tumor size
and positive margins (odds ratio [OR] 1.72 [95 % CI,
0.26–11.45]; P = 0.58).
Association between patient characteristics and extracapsular
extension
Association of patient characteristics with extracapsular
extension in metastatic lymph nodes was assessed
(Table 3). Lymph node size was the only preoperative
characteristic associated with nodal ECE. Smoking his-
tory, p16 status, and the time interval from preoperative
imaging to surgery were not associated with ECE.
Twenty one (62 %) total patients who both had a posi-
tive lymph node detected on preoperative imaging and
also underwent a neck dissection were evaluable for the
examination of the association between preoperativenode size and ECE. Patients with a larger preoperative
node size were more likely to have ECE (mean 3.23 cm
with ECE vs. 1.88 cm without ECE, P < 0.01). ECE was
present more often in patients with a preoperative node
size greater than or equal to vs. less than the median size
of 3.00 cm (92 % vs. 44 %, P = 0.046). Logistic regression
analysis showed that larger preoperative lymph node size
was an independent predictor of ECE (OR 13.32 [95 %
CI, 1.46–121.43]; P = 0.02).
ECE was identified in nine (26 %) patients on imaging
and in 15 (44 %) patients on pathology. ECE was identi-
fied on imaging in eight of the 15 patients with ECE
confirmed on pathology (53 % sensitivity). ECE was ex-
cluded on imaging in 13 of the 14 patients without ECE
on pathology (93 % specificity). In addition the positive
and negative predictive values for the use of imaging to
predict pathologic ECE were 89 and 65 % respectively.
A sensitivity analysis was performed to determine
whether or not these findings would remain robust using
different lymph node size thresholds (Table 4). ECE was
also present more often in patients with a preoperative
node size greater than or equal to vs. less than 2.00 cm
(88 % vs. 20 %, P = 0.01) and in patients with a preopera-
tive node size greater than or equal to vs. less than
2.50 cm (93 % vs. 29 %, P < 0.01).
Discussion
In this series of OPSCC patients undergoing TORS, the
rate of margin positivity was 12 % and the rate of nodal
ECE was 44 %. No clinical features predicted positive mar-
gins in this single institution study of predominantly T1
and T2 cancers, but nodal size emerged as a significant
predictor of ECE. No other clinical features were predict-
ive of ECE. These results appear consistent with those re-
ported from a study of the National Cancer Database
(NCDB) of patients receiving TORS for oropharyngeal
cancer. In that series, the rate of positive margins was
20.2 % in comparison to 12 % in the current study, sug-
gesting our institutional results compare favorably with
national practice patterns. The rate of ECE in the NCDB
study was 28.5 %, although in 17 % of cases the value was
unknown making it difficult to compare it to the 44 %
who had ECE in the current study. Also, only nodal stage,
not largest nodal size was reported in that study, again
making direct comparison difficult [1].
It is a key finding of our study that the previously de-
scribed relationship between nodal size and ECE [16–20]
holds even in a largely HPV-associated oropharyngeal car-
cinoma population. HPV-associated SCC often presents
with thin-walled cystic lymph nodes [21]. It is hypothe-
sized that these cystic lymph nodes carry fewer viable
tumor cells than a solid lymph node of the same size, rais-
ing the question of whether lymph node size would correl-
ate with the risk of ECE in HPV-associated oropharynx
Table 2 Association between patient characteristics and surgical margins (n = 34)
Characteristic Positive margins Negative margins P Value
Age (Mean) 58.0 56.8 .78
Sex
Male 3 (12 %) 22 (88 %) > .99
Female 1 (11 %) 8 (89 %)
Location
Tonsil 1 (6 %) 16 (94 %) .34
Base of Tongue 3 (19 %) 13 (81 %)
Smoking
Smoker 3 (14 %) 18 (86 %) > .99
Non-Smoker 1 (8 %) 12 (92 %)
p16
Positive 3 (11 %) 25 (89 %) > .99
Negative 0 (0 %) 3 (100 %)
Preoperative Tumor Size (Mean) 2.70 cm 2.18 cm .59
Preoperative Tumor Size
Median = 2.20 cm > .99
Less than median size 0 (0 %) 12 (100 %)
Greater than or equal to median size 1 (8 %) 12 (92 %)
Postoperative Tumor Size (Mean) 3.40 cm 2.08 cm .03
Postoperative Tumor Size
Median = 2.20 cm > .99
Less than median size 1 (7 %) 14 (93 %)
Greater than or equal to median size 2 (13 %) 14 (88 %)
Preoperative Node Size (Mean) 2.85 cm 2.89 cm .96
Preoperative Node Size
Median = 3.00 cm > .99
Less than median size 1 (10 %) 9 (90 %)
Greater than or equal to median size 1 (8 %) 12 (92 %)
Postoperative Node Size (Mean) 3.45 cm 3.54 cm .93
Postoperative Node Size
Median = 3.50 cm > .99
Less than median size 1 (13 %) 7 (88 %)
Greater than or equal to median size 1 (9 %) 10 (91 %)
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when HPV was much less prevalent and multiple tumor
sites were studied. The current study, however, demon-
strates that lymph node size remains a strong predictor of
ECE even in a largely HPV-associated population. In the
current study, lymph nodes 3.0 cm and larger were associ-
ated with a rate of ECE of 92 %, which was statistically sig-
nificantly higher than the 44 % rate of ECE seen in smaller
lymph nodes.
In addition to lymph node size, another recently inves-
tigated characteristic has been the correlation between
radiographic ECE on computed tomography (CT)imaging and pathologic ECE. In our study, the use of
radiographic ECE to predict pathologic ECE was associ-
ated with a sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV) of 53,
93, 89, and 65 %, respectively. These findings are fairly
consistent with a recent study of 432 patients with oral
cavity or laryngeal cancer, which demonstrated a sensi-
tivity, specificity, PPV, and NPV of 43.7, 97.7, 82.6, and
87.3 %, respectively, for the use of radiographic ECE to
predict pathologic ECE, though our lower NPV may be
at least partially attributable to the higher prevalence of
pathologic ECE in our study (44 % vs. 20 %). The authors
Table 3 Association between patient characteristics and nodal
extracapsular extension (ECE) (n = 29)
Characteristic ECE No ECE P Value
Age (Mean) 55.5 58.4 .35
Sex
Male 12 (55 %) 10 (46 %) .68
Female 3 (43 %) 4 (57 %)
Location
Tonsil 8 (62 %) 5 (39 %) .48
Base of Tongue 7 (47 %) 8 (53 %)
Smoking
Smoker 9 (53 %) 8 (47 %) > .99
Non-Smoker 6 (50 %) 6 (50 %)
p16
Positive 14 (61 %) 9 (39 %) .56
Negative 1 (33 %) 2 (67 %)
Preoperative Tumor Size (Mean) 2.18 cm 2.13 cm .86
Preoperative Tumor Size
Median = 2.20 cm > .99
Less than median size 6 (55 %) 5 (46 %)
Greater than or equal to median size 4 (50 %) 4 (50 %)
Postoperative Tumor Size (Mean) 1.90 cm 2.26 cm .33
Postoperative Tumor Size
Median = 2.20 cm > .99
Less than median size 8 (53 %) 7 (47 %)
Greater than or equal to median size 6 (50 %) 6 (50 %)
Preoperative Node Size (Mean) 3.23 cm 1.88 cm .002
Preoperative Node Size
Median = 3.00 cm .046
Less than median size 4 (44 %) 5 (56 %)
Greater than or equal to median size 11 (92 %) 1 (8 %)
Postoperative Node Size (Mean) 3.83 cm 2.38 cm .03
Postoperative Node Size
Median = 3.50 cm .02
Less than median size 4 (50 %) 4 (50 %)
Greater than or equal to median size 11 (100 %) 0 (0 %)
Number of Positive Nodes on Imaging
1 10 (71 %) 4 (29 %) > .99
2 or more 5 (71 %) 2 (29 %)
Number of Positive Nodes on Dissection
1 5 (71 %) 2 (29 %) .60
2 or more 10 (83 %) 2 (17 %)
ECE on Imaging
Positive 8 (89 %) 1 (11 %) .01
Negative 7 (35 %) 13 (65 %)
Table 3 Association between patient characteristics and nodal
extracapsular extension (ECE) (n = 29) (Continued)
Node Necrosis on Imaging
Positive 12 (86 %) 2 (14 %) .001
Negative 3 (20 %) 12 (80 %)
ECE indicates extracapsular extension
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ical decision making [22]. In another study of 100 patients
with head and neck cancer, the sensitivity, specificity, PPV,
and NPV by two independent radiologists were (1) 49, 84,
84, and 49 %, respectively, and (2) 65, 54, 71, and 48 %, re-
spectively [23]. The prevalence of pathologic ECE in this
study was 63 %. The authors of this study concluded that
radiographic ECE is not an adequate predictor of patho-
logic ECE due in part to a poor NPV. The criteria used to
identify radiographic ECE in our study and these two
studies were irregular borders of the lymph node capsule
as well as perinodal fat infiltration. Although neither of
these large studies was limited to oropharyngeal cancer
patients and there was a variance in the prevalence of
pathologic ECE between studies, the differing conclusions
demonstrate the contentious nature surrounding the use
of radiographic ECE as a predictor for pathologic ECE.
It should also be noted that debate exists about how the
extent of ECE affects prognosis. A study of mostly p16-
positive oropharyngeal carcinoma demonstrated that
while the risk of recurrence was significantly higher with
grade 4 extracapsular extension (defined as no residual
nodal tissue or architecture, “soft tissue metastases”), this
did not appear to affect disease-free or overall survival
[15]. An unrelated study of larynx and hypopharynx car-
cinoma demonstrated that macroscopic extracapsular ex-
tension, but not microscopic extension, was associated
with risk of recurrence and death [24]. Another study of
35 patients with head and neck squamous cell carcinoma
of unknown primary demonstrated lower overall and
cancer-specific survival in patients with ≥ 2 mm of ECE
[25]. However, a separate study of 266 patients with oral
tongue cancer found no difference in survival when com-
paring patients with ≤ 2 mm vs. > 2 mm of ECE [26].
Current clinical trials use 1 mm of ECE as a cutoff for
analysis [27], and further study is needed in this area.
The findings of the current study, if confirmed in larger
series, can be used to help guide patient selection for
TORS, among patients with T1 and T2 tumors. TORS is a
relatively new technique for operative management of
oropharyngeal tumors with less morbidity and improved
functional outcomes compared to open surgical ap-
proaches for similar tumors [28–31]. Nearly 75 % of newly
diagnosed oropharyngeal cancers are now associated with
HPV and therefore have a more favorable prognosis, lead-
ing to current research studies investigating the benefit of
Table 4 Sensitivity analysis comparing extracapsular extension (ECE) with preoperative node size (n = 21)
Preoperative Node Size ECE No ECE P Value
Less than 2.0 cm 1 (20 %) 4 (80 %) .01
Greater than or equal to 2.0 cm 14 (88 %) 2 (13 %)
Less than 2.5 cm 2 (29 %) 5 (71 %) .006
Greater than or equal to 2.5 cm 13 (93 %) 1 (7 %)
Less than 3.0 cm 4 (44 %) 5 (56 %) .046
Greater than or equal to 3.0 cm 11 (92 %) 1 (8 %)
Less than 3.5 cm 10 (63 %) 6 (38 %) .26
Greater than or equal to 3.5 cm 5 (100 %) 0 (0 %)
Less than 4.0 cm 13 (68 %) 6 (32 %) > .99
Greater than or equal to 4.0 cm 2 (100 %) 0 (0 %)
ECE indicates extracapsular extension
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trials currently underway are investigating the effective-
ness of reduced-dose adjuvant radiation therapy [27] as
well as definitive radiation therapy [32]. In addition, the
association between ECE and prognosis in patients with
p16-positive oropharyngeal cancer has lately been called
into question. Recent retrospective data suggest that ECE
is not associated with disease recurrence or survival in
these patients [33], and this in turn has cast doubt on the
necessity of adjuvant chemoradiation. The question of
whether adjuvant chemoradiation is more beneficial than
adjuvant radiotherapy alone in patients with ECE in the
setting of HPV-related disease is currently being investi-
gated in phase III clinical trials [34, 35]. However, the re-
sults from these studies will not be available for some
time. Unfortunately, the patients in the present study were
treated prior to de-escalation trials for HPV-associated
OPSCC being open at our institution, and so were treated
using a standard of care approach.
Limitations of this study include its retrospective de-
sign and the small sample size. Another consideration is
that the patients in this study underwent TORS during
the first four years of robotic surgery at our institution,
and greater cumulative case volume may lead to im-
proved outcomes. For instance, national data has shown
a lower rate of positive margins in high-volume institu-
tions (defined as having more than 10 TORS cases per
year) compared to low-volume institutions [1], suggest-
ing the existence of a “learning curve.” That said, the
rate of positive margins in our study was favorable to na-
tional rates, suggesting that experience was not the crit-
ical determinant of margin positivity.
Conclusions
The preoperative lymph node size is an independent
predictor of pathologic nodal extracapsular extension in
patients with OPSCC who undergo TORS. Patients with
lymph nodes larger than 3 cm may be more likely tohave pathologic extracapsular extension necessitating
adjuvant chemoradiation, which could put them at a
greater risk of requiring trimodality therapy and its asso-
ciated toxicity. The likelihood of requiring trimodality
therapy should be taken into account along with other
factors such as patient preference, surgical risk, pre-
dicted functional outcomes, and ability to receive
chemotherapy, in order to make an individualized rec-
ommendation for primary TORS or definitive chemora-
diation. These findings are hypothesis-generating and
warrant confirmation in larger, multi-institutional data-
sets. Future prospective studies are needed to evaluate
functional and patient-reported outcomes, and deter-
mine the optimal management of these patients.
Additional file
Additional file 1: Database of TORS patients used for analysis. (XLSX 34 kb)
Abbreviations
ECE, extracapsular extension; HPV, human papillomavirus; NCDB, national cancer
database; NPV, negative predictive value; OPSCC, oropharyngeal squamous cell
carcinoma; PPV, positive predictive value; TORS, transoral robotic surgery
Funding
Funding was provided by the Yale University School of Medicine Medical
Student Research Fellowship. The funding played no role in the design of
the study, in the collection, analysis, and interpretation of data, and in
writing the manuscript.
Availability of data and materials
The dataset supporting the conclusions of this article is included within the
article and its Additional file 1.
Authors’ contributions
All authors made substantial contributions to conception and design, or
acquisition of data, or analysis and interpretation of data; and were involved
in drafting the manuscript or revising it critically for important intellectual
content. All authors read and approved the final manuscript.
Competing interests
Dr. Park has received honoraria and travel expenses from Varian Medical Systems,
Inc. (past). The other authors declare that they have no competing interests.
Subramanian et al. Cancers of the Head & Neck  (2016) 1:7 Page 8 of 8Ethics approval and consent to participate
This study was approved by the Yale University Institutional Review Board,
and informed consent was waived.
Author details
1Department of Therapeutic Radiology, Yale University School of Medicine,
PO Box 208040, New Haven, CT 06510, USA. 2Department of Pathology, Yale
University School of Medicine, New Haven, CT, USA. 3Department of
Diagnostic Radiology, Yale University School of Medicine, New Haven, CT,
USA. 4Section of Otolaryngology, Department of Surgery, Yale University
School of Medicine, New Haven, CT, USA. 5Department of Medical Oncology,
Yale University School of Medicine, New Haven, CT, USA.
Received: 12 April 2016 Accepted: 23 June 2016
References
1. Chen MM, Roman SA, Kraus DH, Sosa JA, Judson BL. Transoral robotic surgery:
a population-level analysis. Otolaryngol Head Neck Surg. 2014;150(6):968–75.
2. Moore EJ, Hinni ML. Critical review: transoral laser microsurgery and robotic-
assisted surgery for oropharynx cancer including human papillomavirus-
related cancer. Int J Radiat Oncol Biol Phys. 2013;85(5):1163–7.
3. Kelly K, Johnson-Obaseki S, Lumingu J, Corsten M. Oncologic, functional
and surgical outcomes of primary Transoral Robotic Surgery for early
squamous cell cancer of the oropharynx: a systematic review. Oral Oncol.
2014;50(8):696–703.
4. Hutcheson KA, Holsinger FC, Kupferman ME, Lewin JS. Functional outcomes
after TORS for oropharyngeal cancer: a systematic review. Eur Arch
Otorhinolaryngol. 2015;272(2):463-71.
5. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent
radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of
the head and neck. N Engl J Med. 2004;350(19):1937–44.
6. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or
without concomitant chemotherapy for locally advanced head and neck
cancer. N Engl J Med. 2004;350(19):1945–52.
7. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced
head and neck cancers: a comparative analysis of concurrent postoperative
radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#
9501). Head Neck. 2005;27(10):843–50.
8. Sinha P, Piccirillo JF, Kallogjeri D, Spitznagel EL, Haughey BH. The role of
postoperative chemoradiation for oropharynx carcinoma: a critical appraisal
of the published literature and National Comprehensive Cancer Network
guidelines. Cancer. 2015;121(11):1747–54.
9. Quon H, O'Malley Jr BW, Weinstein GS. Postoperative adjuvant therapy after
transoral robotic resection for oropharyngeal carcinomas: rationale and current
treatment approach. ORL J Otorhinolaryngol Relat Spec. 2011;73(3):121–30.
10. O'Sullivan B, Huang SH, Siu LL, et al. Deintensification candidate subgroups
in human papillomavirus-related oropharyngeal cancer according to
minimal risk of distant metastasis. J Clin Oncol. 2013;31(5):543–50.
11. Psyrri A, Rampias T, Vermorken JB. The current and future impact of human
papillomavirus on treatment of squamous cell carcinoma of the head and
neck. Ann Oncol. 2014;25(11):2101–15.
12. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and
rising oropharyngeal cancer incidence in the United States. J Clin Oncol.
2011;29(32):4294–301.
13. Wooten CE, Wilson WA, Arnold SM, et al. Functional outcomes with surgical
and Non-surgical management of locally advanced oropharyngeal cancer.
Int J Radiat Oncol Biol Phys. 2014;90(1):S123.
14. Lukens JN, Lin A, Gamerman V, et al. Late consequential surgical bed soft
tissue necrosis in advanced oropharyngeal squamous cell carcinomas
treated with transoral robotic surgery and postoperative radiation therapy.
Int J Radiat Oncol Biol Phys. 2014;89(5):981–8.
15. Lewis Jr JS, Carpenter DH, Thorstad WL, Zhang Q, Haughey BH.
Extracapsular extension is a poor predictor of disease recurrence in
surgically treated oropharyngeal squamous cell carcinoma. Mod Pathol.
2011;24(11):1413–20.
16. Johnson JT, Barnes EL, Myers EN, Schramm Jr VL, Borochovitz D, Sigler BA.
The extracapsular spread of tumors in cervical node metastasis. Arch
Otolaryngol. 1981;107(12):725–9.
17. Snow GB, Annyas AA, van Slooten EA, Bartelink H, Hart AA. Prognostic factors
of neck node metastasis. Clin Otolaryngol Allied Sci. 1982;7(3):185–92.18. Snyderman NL, Johnson JT, Schramm Jr VL, Myers EN, Bedetti CD, Thearle P.
Extracapsular spread of carcinoma in cervical lymph nodes. Impact upon
survival in patients with carcinoma of the supraglottic larynx. Cancer. 1985;
56(7):1597–9.
19. Carter RL, Bliss JM, Soo KC, O'Brien CJ. Radical neck dissections for
squamous carcinomas: pathological findings and their clinical implications
with particular reference to transcapsular spread. Int J Radiat Oncol Biol
Phys. 1987;13(6):825–32.
20. Hirabayashi H, Koshii K, Uno K, et al. Extracapsular spread of squamous cell
carcinoma in neck lymph nodes: prognostic factor of laryngeal cancer.
Laryngoscope. 1991;101(5):502–6.
21. Koch WM. Clinical features of HPV-related head and neck squamous cell
carcinoma: presentation and work-up. Otolaryngol Clin North Am. 2012;
45(4):779–93.
22. Prabhu RS, Magliocca KR, Hanasoge S, et al. Accuracy of computed
tomography for predicting pathologic nodal extracapsular extension in
patients with head-and-neck cancer undergoing initial surgical resection. Int
J Radiat Oncol Biol Phys. 2014;88(1):122–9.
23. Chai RL, Rath TJ, Johnson JT, et al. Accuracy of computed tomography in
the prediction of extracapsular spread of lymph node metastases in
squamous cell carcinoma of the head and neck. JAMA Otolaryngol Head
Neck Surg. 2013;139(11):1187–94.
24. Brasilino de Carvalho M. Quantitative analysis of the extent of extracapsular
invasion and its prognostic significance: a prospective study of 170 cases of
carcinoma of the larynx and hypopharynx. Head Neck. 1998;20(1):16–21.
25. Keller LM, Galloway TJ, Holdbrook T, et al. p16 status, pathologic and clinical
characteristics, biomolecular signature, and long-term outcomes in head
and neck squamous cell carcinomas of unknown primary. Head Neck. 2014;
36(12):1677–84.
26. Greenberg JS, Fowler R, Gomez J, et al. Extent of extracapsular spread: a
critical prognosticator in oral tongue cancer. Cancer. 2003;97(6):1464–70.
27. Eastern Cooperative Oncology Group; National Cancer Institute. Transoral
surgery followed by low-dose or standard-dose radiation therapy with or
without chemotherapy in treating patients with HPV positive stage III-IVA
oropharyngeal cancer. In: ClinicalTrials.gov [Internet]. Bethesda: National
Library of Medicine (US). 2013 [cited 2015 Dec 20]. Available from: https://
clinicaltrials.gov/ct2/show/NCT01898494.
28. Weinstein GS, O'Malley Jr BW, Desai SC, Quon H. Transoral robotic surgery:
does the ends justify the means? Curr Opin Otolaryngol Head Neck Surg.
2009;17(2):126–31.
29. Moore EJ, Olsen KD, Kasperbauer JL. Transoral robotic surgery for
oropharyngeal squamous cell carcinoma: a prospective study of feasibility
and functional outcomes. Laryngoscope. 2009;119(11):2156–64.
30. Moore EJ, Olsen SM, Laborde RR, et al. Long-term functional and oncologic
results of transoral robotic surgery for oropharyngeal squamous cell
carcinoma. Mayo Clin Proc. 2012;87(3):219–25.
31. Weinstein GS, O'Malley Jr BW, Snyder W, Sherman E, Quon H. Transoral
robotic surgery: radical tonsillectomy. Arch Otolaryngol Head Neck Surg.
2007;133(12):1220–6.
32. NRG Oncology; National Cancer Institute. Reduced-dose intensity-
modulated radiation therapy with or without cisplatin in treating patients
with advanced oropharyngeal cancer. In: ClinicalTrials.gov [Internet].
Bethesda: National Library of Medicine (US). 2014 [cited 2016 May 20].
Available from: https://clinicaltrials.gov/ct2/show/NCT02254278.
33. Sinha P, Kallogjeri D, Gay H, et al. High metastatic node number, not
extracapsular spread or N-classification is a node-related prognosticator in
transorally-resected, neck-dissected p16-positive oropharynx cancer. Oral
Oncol. 2015;51(5):514–20.
34. Washington University School of Medicine. Post Operative Adjuvant
Therapy De-intensification Trial for Human Papillomavirus-related, p16+
Oropharynx Cancer (ADEPT). In: ClinicalTrials.gov [Internet]. Bethesda:
National Library of Medicine (US). 2012 [cited 2015 Aug 20]. Available from:
https://clinicaltrials.gov/ct2/show/NCT01687413.
35. Owadally W, Hurt C, Timmins H, et al. PATHOS: a phase II/III trial of risk-
stratified, reduced intensity adjuvant treatment in patients undergoing
transoral surgery for Human papillomavirus (HPV) positive oropharyngeal
cancer. BMC Cancer. 2015;15:602.
